IRIS
PALUMBO, Giuseppe Alberto Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.060
EU - Europa 3.840
AS - Asia 3.042
SA - Sud America 593
AF - Africa 380
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 7
Totale 15.934
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.801
SG - Singapore 1.693
IT - Italia 1.396
IE - Irlanda 960
CN - Cina 956
UA - Ucraina 554
BR - Brasile 540
CI - Costa d'Avorio 249
CA - Canada 224
RU - Federazione Russa 212
DE - Germania 158
SE - Svezia 130
KR - Corea 80
IN - India 78
FI - Finlandia 75
SN - Senegal 75
GB - Regno Unito 62
VN - Vietnam 60
BE - Belgio 49
FR - Francia 49
CH - Svizzera 39
NL - Olanda 36
CZ - Repubblica Ceca 30
MX - Messico 23
AR - Argentina 20
AT - Austria 20
JP - Giappone 20
NG - Nigeria 20
UZ - Uzbekistan 18
BD - Bangladesh 17
TR - Turchia 17
ES - Italia 15
GR - Grecia 15
HK - Hong Kong 14
PK - Pakistan 14
PL - Polonia 14
IQ - Iraq 13
LB - Libano 13
AU - Australia 11
MA - Marocco 11
ZA - Sudafrica 10
CO - Colombia 9
IR - Iran 8
JO - Giordania 8
KE - Kenya 8
EU - Europa 7
IL - Israele 7
EC - Ecuador 6
VE - Venezuela 6
AE - Emirati Arabi Uniti 5
BG - Bulgaria 5
EG - Egitto 5
LT - Lituania 4
RO - Romania 4
SA - Arabia Saudita 4
TT - Trinidad e Tobago 4
AZ - Azerbaigian 3
CL - Cile 3
HN - Honduras 3
NO - Norvegia 3
PY - Paraguay 3
AM - Armenia 2
BO - Bolivia 2
DO - Repubblica Dominicana 2
MY - Malesia 2
OM - Oman 2
PS - Palestinian Territory 2
PT - Portogallo 2
UY - Uruguay 2
AL - Albania 1
BB - Barbados 1
DK - Danimarca 1
DZ - Algeria 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
JM - Giamaica 1
KG - Kirghizistan 1
KZ - Kazakistan 1
LU - Lussemburgo 1
MD - Moldavia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PH - Filippine 1
RS - Serbia 1
SC - Seychelles 1
SI - Slovenia 1
SK - Slovacchia (Repubblica Slovacca) 1
SV - El Salvador 1
TH - Thailandia 1
Totale 15.934
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.451
Singapore 1.048
Dublin 935
Chandler 923
Houston 780
Jacksonville 533
Chicago 527
Boardman 386
Catania 325
Ashburn 293
Abidjan 249
Lawrence 248
Cambridge 245
Andover 241
Nanjing 212
Toronto 151
Hefei 139
Civitanova Marche 132
Des Moines 129
Wilmington 107
San Mateo 90
Rome 83
Seoul 80
Dakar 75
Nanchang 72
Milan 69
The Dalles 63
Florence 57
Saint Petersburg 57
Shenyang 57
Beijing 55
Hebei 54
Jiaxing 52
Columbus 51
Ottawa 49
Los Angeles 48
Brussels 46
Grafing 46
Munich 45
Changsha 41
Dong Ket 40
Washington 39
São Paulo 37
Palermo 35
Tianjin 34
Falls Church 29
Helsinki 29
Council Bluffs 27
Messina 27
Seattle 27
Lappeenranta 23
Turku 23
Kochi 21
Abuja 20
Moscow 20
Bronte 18
Den Haag 18
Naples 18
New York 17
Brno 16
Rio de Janeiro 16
San Francisco 16
Bari 15
Bremen 15
Boston 14
Hanoi 14
Jinan 14
Turin 14
Ann Arbor 13
Brooklyn 13
Hong Kong 13
Amsterdam 12
Belo Horizonte 12
Pune 12
Tokyo 12
Augusta 11
Guangzhou 11
Mexico City 11
Misterbianco 11
Curitiba 10
Kunming 10
Mumbai 10
Norwalk 10
Paris 10
Aci Sant'Antonio 9
Stockholm 9
Amman 8
Campinas 8
Fukuoka 8
Genoa 8
Goiânia 8
Hangzhou 8
Mascalucia 8
Montreal 8
Olomouc 8
Redwood City 8
Ardabil 7
Atlanta 7
Bernareggio 7
Cassano delle Murge 7
Totale 11.187
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 233
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes 213
Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population 192
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 168
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 152
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 125
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 119
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 111
IGFBP-6 Alters Mesenchymal Stromal Cell Phenotype Driving Dasatinib Resistance in Chronic Myeloid Leukemia 104
Focus on Osteosclerotic Progression in Primary Myelofibrosis 100
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 96
In vitro apoptotic response of freshly isolated chronic myeloid leukemia cells to all-trans retinoic acid and cytosine arabinoside 95
Terapia del mieloma multiplo 92
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 91
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 91
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 90
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 89
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 88
A cytoprotective role for the heme oxygenase-1/CO pathway during neural differentiation of human mesenchymal stem cells 87
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 86
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 85
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 84
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 83
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 83
ACVR1: A Novel Therapeutic Target to Treat Anemia in Myelofibrosis 82
A physiological role for the neuropeptide luteinizing hormone-releasing hormone (LHRH) during the maturation of thymus Gland function 82
Hedgehog signaling pathways in multiple myeloma 81
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 81
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 80
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 78
Pyrrolidinedithiocarbamate induces apoptosis in human acute myelogenous leukemic cells affecting NF-kappaB activity 78
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 78
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 78
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 77
Prognostic value of CD34+ peak in peripheral blood during mobilization in intermediate-risk AML patients treated in first CR by autologous or allogeneic transplantation 77
Correction: TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma (Cell Death & Disease, (2019), 10, 10, (704), 10.1038/s41419-019-1959-5) 77
Adherence to ruxolitinib, an oral JAK1/2 inhibitor, in patients with myelofibrosis: interim analysis from an Italian, prospective cohort study (ROMEI) 77
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 76
ITF2357 Interferes with apoptosis and inflammatory pathways in the HL-60 model: A gene expression study 76
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 75
Effects of imatinib mesylate in osteoblastogenesis 74
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 74
Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS): phase 1 results of a single-blind, randomised, controlled, phase 2 superiority trial 74
Additional Genetic Alterations and Clonal Evolution of MPNs with Double Mutations on the MPL Gene: Two Case Reports 73
Angiogenesis in acute myeloid leukemia 73
Emangioma, plasmocitoma e mieloma multiplo del rachide 73
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 72
PREDICTORS FOR RESPONSE TO RUXOLITINIB IN REAL-LIFE: AN OBSERVATIONAL INDEPENDENT STUDY ON 266 PATIENTS WITH MYELOFIBROSIS 72
Mesenchymal Stem Cells (MSC) Regulate Activation of Granulocyte-Like Myeloid Derived Suppressor Cells (G-MDSC) in Chronic Myeloid Leukemia Patients 71
HIGH-RESOLUTION SNP ARRAYS AS AN ADDITIONAL TOOL TO SEARCH FOR GENETIC DEFECTS INVOLVED IN PROGRESSION FROM MYELODYSPLASTIC SINDROME TO ACUTE LEUKEMIA 71
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 71
Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations 71
Accuracy of physician assessment of treatment preferences and health status in elderly patients with higher-risk myelodysplastic syndromes 71
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: An ex-vivo study 71
Targeted Metabolomics Highlights Dramatic Antioxidant Depletion, Increased Oxidative/Nitrosative Stress and Altered Purine and Pyrimidine Concentrations in Serum of Primary Myelofibrosis Patients 70
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 70
Hypoxia Induces Imatinib Resistance in CML Cell Lines 70
Different in vitro alemtuzumab induced apoptosis on T and B lymphocytes of B-CLL patients 70
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 70
IMATINIB INCREASES CYTOTOXICITY OF MELPHALAN AND DECREASES PROLONGATION OF G2-M PHASE IN HUMAN K562 CELLS 69
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 69
Off-Label Use of Venetoclax in Patients With Acute Myeloid Leukemia: Single Center Experience and Data From Pharmacovigilance Database 69
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 68
In vitro sensitivity of B-CLL cells to Fludarabine and Interferons 68
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients 67
Multidrug resistance mechanisms in chronic lymphocytic leukaemia 67
ANTITUMOR ACTIVITY OF BORTEZOMIB ALONE AND IN COMBINATION WITH TRAIL IN HUMAN ACUTE MYELOID LEUKEMIA C.M.S 67
Evaluation of taxol cytotoxicity on B-CLL cells in vitro 67
Antitumor Activity of Bortezomib Alone and in Combination with TRAIL in Human Acute Myeloid Leukemia 67
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 66
Cross-talk communication in the neuroendocrine-reproductive-immune axis. Age-dependent alterations in the common communication networks. 66
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 66
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 65
Monocytic Myeloid Derived Suppressor CELLS (M-MDSC) As Prognostic Factor in Chronic Myeloid Leukemia Patients Treated with Dasatinib 65
IMPACT OF EPOETIN ZETA (BIOSIMILAR EPO alpha) IN LOW-RISK MDS: ITT ANALYSIS OF A MULTICENTRIC PHASE 2 STUDY 65
Peptidergic modulation of immune system development: role of luteinizing hormone-releasing hormone. 65
The NLR and LMR ratio in newly diagnosed MM patients treated upfront with novel agents 65
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 65
Effects of micronised microencapsulated ferric pyrophosphate supplementation in patients with advanced cancer and iron deficiency: A single-centre cohort pilot study 65
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project 64
Target Therapy for Extramedullary Relapse of FLT3-ITD Acute Myeloid Leukemia: Emerging Data from the Field 64
Il mitoxantrone in polichemioterapia associato allo schema CVP nel trat- tamento dei linfomi non hodgkin. 64
MONOCYTIC MYELOID DERIVED SUPPRESSOR CELLS (M-MDSC) AS PROGNOSTIC FACTOR IN DASATINIB TREATED PATIENTS WITH CHRONIC MYELOID LEUKEMIA 63
Neuroprotective Role of α-Lipoic Acid in Iron-Overload-Mediated Toxicity and Inflammation in In Vitro and In Vivo Models 62
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 62
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 62
Proteomic analysis reveals autophagy as pro-survival pathway elicited by long-term exposure with 5-azacitidine in high-risk myelodysplasia 62
The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study 62
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients 62
Endothelial Dysfunction after Hematopoietic Stem Cell Transplantation: A Review Based on Physiopathology 61
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 61
BROAD COPY NEUTRAL-LOSS OF HETEROZYGOSITY REGIONS AND RARE RECURRING COPY NUMBER ABNORMALITIES IN KARYOTYPICALLY NORMAL ACUTE MYELOID LEUKEMIA GENOMES 61
Effects of proton irradiations on functional characteristics of bone marrow mesenchimal stem cells 61
THE ROLE OF SPARC IN CHRONIC MYELOID LEUKEMIA 61
Nuclear translocation of Heme oxygenase-1 confers resistance to imatinib in chronic myeloid leukemia cells 60
HISTONE DEACETYLASE INHIBITOR ITF2357 EXERT SIGNIFICANT ANTI-PROLIFERATIVE AND PRO-APOPTOTIC EFFECTS ON THE P39 CELL LINE: A GENE EXPRESSION STUDY 60
The Neutrophil-to-Lymphocyte Ratio is Related to Disease Activity in Relapsing Remitting Multiple Sclerosis 60
Molecular pathogenesis and treatment perspectives for hypereosinophilia and hypereosinophilic syndromes 60
Saprochete capitata: Emerging Infections from Uncommon Microorganisms in Hematological Diseases 59
Low serum levels of vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF) in IFN-treated chronic myeloid leukemia (CML) patients 59
Totale 7.992
Salva come PNG Salva come JPEG
Categoria #
all - tutte 67.945
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 67.945
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.115 20 85 107 49 367 16 118 13 131 12 117 80
2021/20221.799 150 246 2 13 363 38 271 77 158 32 35 414
2022/20233.042 278 147 73 212 249 522 28 515 738 56 154 70
2023/20241.805 111 246 93 127 87 339 97 133 10 51 320 191
2024/20256.208 56 954 344 315 1.336 633 219 234 442 614 527 534
2025/2026205 205 0 0 0 0 0 0 0 0 0 0 0
Totale 16.446